Vanguard Co V News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ Romark announced today that results of its Vanguard Co-V clinical trial of NT-300 (nitazoxanide extended-release tablets, 300 mg) for treatment.

Puerto ricoUnited statesAr raqqahPrnewswire romarkIcahn school of medicine at mount sinaiBoston university school of medicineHarvard medical schoolUniversity of texas medical branchInfect public healthVanguard co vChief medicalScientific officerIcahn schoolMount sinaiPublic healthBoston university school